Summary
AbbVie Inc. (ABBV) has filed a Current Report (8-K) on January 6, 2025, providing a crucial update on its financial performance, specifically concerning the fourth quarter of 2024. The company anticipates significant acquired IPR&D (In-Process Research & Development) and milestones expenses, estimated at $1.6 billion on a pre-tax basis. This expense is expected to negatively impact both GAAP and adjusted non-GAAP diluted earnings per share by $0.88 each. Investors should note that these are preliminary estimates and the final results may differ. The company has also revised its full-year 2024 adjusted diluted earnings per share guidance to a range of $10.02 - $10.06, incorporating this substantial fourth-quarter expense. The updated fourth-quarter 2024 adjusted diluted earnings per share guidance is now projected to be between $2.06 - $2.10. This filing highlights the financial impact of strategic acquisitions and licensing agreements, which, while strategically important for future growth, introduce a degree of variability and expense that was not previously forecast beyond the third quarter of 2024.
Key Highlights
- 1AbbVie expects significant acquired IPR&D and milestones expenses of $1.6 billion (pre-tax) in Q4 2024.
- 2These expenses are projected to reduce both GAAP and adjusted non-GAAP diluted EPS by $0.88 for Q4 2024.
- 3Full-year 2024 adjusted diluted EPS guidance is revised to $10.02 - $10.06, reflecting the Q4 expense.
- 4Q4 2024 adjusted diluted EPS guidance is now $2.06 - $2.10.
- 5The company notes these are preliminary estimates and final results may vary.
- 6The acquired IPR&D and milestones expense was not previously forecast beyond Q3 2024.